Opaleye Management Inc. bought a new stake in shares of Uniqure NV (NASDAQ:QURE) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 90,801 shares of the biotechnology company’s stock, valued at approximately $1,778,000. Uniqure comprises 0.6% of Opaleye Management Inc.’s investment portfolio, making the stock its 28th largest position.
A number of other hedge funds have also added to or reduced their stakes in the stock. SG Americas Securities LLC acquired a new stake in Uniqure during the fourth quarter valued at approximately $119,000. JPMorgan Chase & Co. lifted its stake in Uniqure by 33.5% during the second quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after purchasing an additional 14,659 shares during the last quarter. Virtus Fund Advisers LLC acquired a new stake in Uniqure during the fourth quarter valued at approximately $389,000. OxFORD Asset Management LLP acquired a new stake in Uniqure during the third quarter valued at approximately $399,000. Finally, FMR LLC lifted its stake in Uniqure by 4.1% during the second quarter. FMR LLC now owns 1,560,113 shares of the biotechnology company’s stock valued at $9,656,000 after purchasing an additional 61,650 shares during the last quarter. 34.57% of the stock is owned by institutional investors and hedge funds.
In other news, CEO Matthew C. Kapusta sold 21,690 shares of the business’s stock in a transaction that occurred on Thursday, January 4th. The shares were sold at an average price of $19.87, for a total transaction of $430,980.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Maria E. Cantor sold 5,864 shares of the business’s stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $20.13, for a total transaction of $118,042.32. The disclosure for this sale can be found here. Insiders have sold 41,510 shares of company stock worth $815,776 in the last 90 days. 0.73% of the stock is owned by company insiders.
QURE has been the subject of several recent research reports. Leerink Swann increased their target price on shares of Uniqure from $19.00 to $26.00 in a research note on Tuesday, November 7th. HC Wainwright initiated coverage on shares of Uniqure in a research note on Friday, December 1st. They set a “buy” rating and a $28.00 target price for the company. BidaskClub raised shares of Uniqure from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Janney Montgomery Scott initiated coverage on shares of Uniqure in a research note on Wednesday, January 3rd. They set a “buy” rating and a $25.00 target price for the company. Finally, Zacks Investment Research raised shares of Uniqure from a “hold” rating to a “buy” rating and set a $20.00 target price for the company in a research note on Tuesday, February 6th. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Uniqure has an average rating of “Buy” and a consensus target price of $19.88.
COPYRIGHT VIOLATION NOTICE: “90,801 Shares in Uniqure NV (QURE) Purchased by Opaleye Management Inc.” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2018/02/20/90801-shares-in-uniqure-nv-qure-purchased-by-opaleye-management-inc.html.
Uniqure Company Profile
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Uniqure NV (NASDAQ:QURE).
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.